Rubius Therapeutics, Inc.

Flagship Pioneering Innovations V, Inc.

Massachusetts Institute of Technology

University of Iowa Research Foundation

The Broad Institute, Inc.

Editas Medicine, Inc.

Jordi Mata-Fink

Avak Kahvejian

Noubar Boghos Afeyan

John Round

David Arthur Berry

Jonathan Barry Hurov

Chengyi Jenny Shu

Sivan Elloul

Julian Alexander Stanley

Tiffany F Chen

George Huck Neubauer

Tom Wickham

Feng Zhang

Beverly L Davidson

Robert J Deans

Alexis Borisy

Edgardo Rodriguez

Deborah Palestrant

Torben Straight Nissen

Nathan Dowden

Manuel Andreas Fankhauser

Eric Franklin Zhu

Lenka Hoffman

Xuqing Zhang

Carolyn Sayre

Billy Law

Kristian Eric Teichert

Shamael Rabia Dastagir

Katherine Mary Molloy

Alexandra Lantermann

Provided are cells containing exogenous antigen and uses thereof.

Methods and compositions for immunomodulation

Disclosed herein are methods and compositions useful in targeting a payload to, or editing a target nucleic acid, where a governing gRNA molecule is used to target, optionally inactivate, a Cas9 molecule or a Cas9 molecule/gRNA complex.

CRISPR-related methods and compositions with governing gRNAS

The present invention provides methods for treating inflammatory or autoimmune disease using calcitonin receptor activators, such as calcitonin receptor activating antibodies, among others. The invention also features compositions containing calcitonin receptor activators, methods of diagnosing patients with calcitonin receptor-associated inflammatory or autoimmune disease, and methods of predicting the response of an inflammatory or autoimmune disease or condition in a subject to treatment with calcitonin receptor activators.

Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators

The present invention provides methods for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators, such as serotonin receptor activating antibodies, among others. The invention also features compositions containing serotonin receptor activators, methods of diagnosing patients with a serotonin receptor-associated inflammatory or autoimmune disease or condition, and methods of predicting the response of an inflammatory or autoimmune disease or condition in a subject to treatment with serotonin receptor activators.

Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators

The present invention provides methods for treating inflammatory or autoimmune disease using mGluR8 activators, such as mGluR8 activating antibodies, among others. The invention also features compositions containing mGluR8 activators, methods of diagnosing patients with mGluR8-associated inflammatory or autoimmune disease, and methods of predicting the response of an inflammatory or autoimmune disease or condition in a subject to treatment with mGluR8 activators.

Methods and compositions for treating inflammatory or autoimmune diseases or conditions using GRM8 activators

The present invention provides methods for treating cancer using serotonin receptor inhibitors, such as serotonin receptor inhibitory antibodies, among others. The invention also features compositions containing serotonin receptor inhibitors, methods of diagnosing patients with serotonin receptor-associated cancer, and methods of predicting the response of cancer in a subject to treatment with serotonin receptor inhibitors.

Methods and compositions for treating cancer using serotonin receptor inhibitors

Described herein are novel preparations of functionalized erythroid cells and related compositions, reagents, and methods for use in human pharmaceutical and veterinary applications.

Functionalized erythroid cells

The present invention provides methods for treating cancer using sarco/endoplasmic reticulum Ca-ATPase (SERCA) pump inhibitors, such as SERCA pump inhibitory antibodies, among others. The invention also features compositions containing SERCA pump inhibitors, methods of diagnosing patients with SERCA pump-associated cancer, and methods of predicting the response of cancer in a subject to treatment with SERCA pump inhibitors.

Methods and compositions for treating cancer using SERCA pump inhibitors

The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.

Compositions and methods related to multimodal therapeutic cancer indications

The present invention provides methods for treating cancer using mGluR8 inhibitors, such as mGluR8 inhibitory antibodies and small molecules. The invention also features compositions containing mGluR8 inhibitors, methods of diagnosing patients with mGluR8-associated cancer, and methods of predicting the response of cancer in a subject to treatment with mGluR8 inhibitors.

Methods for treating cancer using GRM8 inhibitors

CRISPR-related methods and compositions with governing gRNAs

Compositions and methods related to engineered erythroid cells comprising IL-15

Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.

Erythroid cells comprising phenylalanine ammonia lyase

Growing community of inventors

Somerville, MA, United States of America

Jordi Mata-Fink